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ANA: Anti-nuclear autoantibody 
ADAM: A disintegrin and metalloproteinase 
APC: Antigen-presenting cell 
B/W: Mice of the (New Zealand Black x New Zealand White)F1 progeny 
DAMP: Damage-associated molecular pattern 
DIF: Direct immunofluorescence 
DKK: Dickkopf 
Dnase: Deoxyribonuclease 
dsDNA: Double-stranded DNA 
ECM: Extracellular matrix 
EDS: Electron-dense structure 
GBM: Glomerular basement membrane 
GSK3b: Glycogen synthase kinase 3b 
HSPG; Heparan sulphate proteoglycans 
IC: Immune complex 
ISR: International Society of Nephrology 
JNK: c-Jun N-terminal kinase 
LN: Lupus nephritis 
LRP: LDL receptor-resembling protein 
MHC: Major histocompatibility complex 
MMP: Matrix metalloproteinase 
mRNA: Messenger RNA 
PAMP: Pathogen-associated molecular pattern 
RES: Reticulo-endothelial system 
RPS: Renal Pathology Society 
SDS: Sodium dodecyl sulphate 
sFRP: Secreted frizzled protein 
SLE: Systemic lupus erythematosus 
TdT: Terminal deoxynucleotidyl transferase 
TIMP: Tissue inhibitor of metalloproteinases 
TLR: Toll-like receptor  
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling 
UUO: Unilateral uretheral obstruction 









4.1 Historical perspectives 
The history of systemic lupus erythematosus (SLE) dates back to medieval times, 
with accounts of women with a characteristic symmetrical erythematous rash of the 
cheeks and nasal bridge, resembling a wolves (Latin: lupus) bite. The first detailed 
descriptions of the disease are found in the writings of medical pioneers of the late 
1800s, including Móric Kaposi and Sir William Osler, as reviewed in [1]. In the more 
than 100 years that have passed since Osler’s papers describing the many facets of 
this complex disease, SLE has been a subject of great fascination and frustration 
amongst medical researchers and clinicians worldwide. 
 It was not until 1948 that dr. Hargraves, a physician at the Mayo Clinic, made 
the first observations identifying SLE as an autoimmune disease [2]. In the late 50s, it 
was discovered that lupus patients had high levels of circulating autoantibodies 
against nuclear structures (anti-nuclear autoantibodies; ANA), and diagnostic 
immunofluorescence assays were developed for the demonstration of ANAs. Closer 
examinations of the binding targets of ANAs revealed a particular affinity for double-
stranded DNA (dsDNA) and histone peptides. Although ANAs are found in several 
systemic autoimmune disorders, anti-dsDNA autoantibodies displayed a very high 
specificity for SLE. Since then, the basis for the emergence of autoreactivity against 
double-stranded DNA (dsDNA) has been one of the main topics in SLE research.  
 One of the most common manifestations of SLE and a major contributor to the 
morbidity and mortality of the disease, lupus nephritis (LN) is the end-organ disease 
that has been most extensively investigated. The most apparent feature of the renal 
disease is the development of glomerulonephritis, associated with the deposition of 
autoantibodies within glomerular membranes.  
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4.2 Epidemiology and classification of SLE 
4.2.1 General features 
SLE is a disease of the young, with 85% of patients developing the disease before the 
age of 55 [3], of which 20% are children below 16 years of age [4]. Estimates of the 
prevalence of SLE vary greatly, ranging from 20 to 150 per 100 000 [5,6], higher 
among Afro-Americans and Asians. The incidence has risen threefold during the last 
40 years, owing to improved detection of mild disease [7]. A sex hormone influence 
on pathogenesis is assumed based on the 7:1 to 15:1 female-to-male ratio of SLE [8]. 
In further support of this view, in children the female-to-male ratio is 3:1 [9]. 
 Susceptibility for SLE development is assumed to have a genetic basis, 
however concordance rate estimates in monozygotic twins vary greatly (14-69%) 
[10]. These figures are similar to those found for other autoimmune diseases. Several 
SLE predisposing loci have been identified, of which the major histocompatibility 
complex (MHC) locus is the most prominent. Apart from very rare single gene 
mutations that cause lupus-like diseases (reviewed in [11]), no single gene 
polymorphism has been identified that by itself causes high SLE susceptibility. 
  
4.2.2 Diagnostic and prognostic markers in SLE 
SLE can manifest itself by a wide variety of symptoms, affecting virtually any organ, 
and the pattern of symptoms may vary considerably over time. The most commonly 
involved tissues include skin, the musculoskeletal and hematological system, kidneys, 
the cardiovascular system and the central nervous system. 
 The diagnosis of SLE can be challenging, especially in patients presenting 
with symptoms from only one organ or with ill-defined systemic complaints. A 
classification scoring system has been developed that includes the most commonly 
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observed clinical and serological disease manifestations. This system was developed 
by the American College of Rheumatology (ACR) for the purpose of classification in 
clinical studies, and not as a diagnostic tool, but is still widely utilized by clinicians as 
an aid in establishing the diagnosis of SLE [12]. The 11 ACR criteria in their latest, 
revised form [13] are listed in Appendix 1. For a definitive diagnosis of SLE, 4 or 
more criteria should be fulfilled. Given the dynamic nature of SLE manifestations, not 
all criteria need to be present at the same time. 
 
4.3 Pathophysiology of SLE 
4.3.1 Emergence and maintenance of autoimmunity 
The models to explain SLE pathogenesis are as varied as they are many, which seems 
to be the case for several of the autoimmune diseases. Classically, they include i) 
infectious processes in which cross-reactivity against self antigens is responsible for 
autoimmune reactions [14], ii) disturbances in lymphocyte regulation that generates a 
state of immunological hyper-reactivity, iii) environmental effects [15], and iv) 
genetic disturbances in various aspects of tissue homeostasis. During the last decade, 
research has been largely focused on the latter type of models, which will therefore be 
the focus of the following discussion and for the analysis of the present results.  
The mechanisms underlying the appearance of circulating autoantibodies against 
nuclear structures, and dsDNA in particular, is by many considered the key to 
understanding SLE. Indeed, studies have shown that the presence of circulating 
DNA/anti-dsDNA immune complexes maintained by repeated injections can mimic 
SLE manifestations such as glomerular immune complex deposition and the 
development of proteinuria [16]. Of note, renal disease is reversed upon terminating 
the injections. Similarly, injection of monoclonal autoantibodies isolated from SLE 
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patients and B/W mice cause reversible proteinuria, most likely by binding to their 
antigen targets forming immune complexes, either within the circulation or locally 
within the kidneys [17,18,19]. 
 The dominance of nuclear autoantigens and the presence of chromatin-
associated antigens in immune complex deposits in SLE has led to the hypothesis that 
deficiencies in the clearance of dying cells serves as a source of autoreactivity. 
Normal cell death through apoptosis is a well-orchestrated process in which cellular 
antigens are rapidly degraded within intact membranes. The release of chromatin into 
the extracellular milieu triggers inflammation through the exposure of so-called 
danger signals [20,21,22]. These are endogenous structures that are exposed within 
the extracellular milieu in the setting of various kind of cellular damage, and include a 
growing number of substances including high-mobility-group box 1, heat shock 
proteins and uric acid, as reviewed in [23]. Release of danger signals can occur during 
necrotic cell death, which disrupts cellular membranes and causes leakage of 
intracellular debris. During apoptosis, however, efficient degradation of chromatin by 
endonucleases is considered one of the hallmarks of the early stages of cell death. 
Apoptotic cells are efficiently cleared by phagocytosis by tissue macrophages 
and to various extents by other cell types. If phagocytosis is inhibited, retained 
apoptotic cell fragments will degrade, undergo secondary necrotic transformation, and 
trigger the release of pro-inflammatory factors including chromatin [24]. Previous 
studies have found clearance of apoptotic cells to be impaired in SLE patients 
[25,26,27,28]. Similarly, patients with genetic deficiencies of the complement factor 
C1q which is involved in the uptake of apoptotic cells by phagocytosing cells 
commonly develop SLE [29]. Blood from SLE patients have increased levels of 
apoptotic leukocytes [30,31]. Taken together, these data suggests the occurrence of an 
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apoptotic cell clearance deficiency in SLE. Under circumstances of increased 
apoptotic cell loads, such a deficiency would provide a source of secondary necrotic 
cells, trigging inflammation and the development and maintenance of autoimmunity 
[32]. Such a model might explain the tendency of various types of tissue damage, 
including trauma, infections [33] or ultraviolet light [34] to cause “disease flares” [35] 
in SLE.  
 
4.3.2 Production, elimination and deposition of immune complexes 
Immune complexes are generated by the interaction of antibodies and soluble forms 
of the corresponding antigen. Such complexes may form within the circulation or 
locally within the tissues. The size and solubility of immune complexes is determined 
by the molar ratio of antigen to antibodies as well as the size and number of binding 
sites on the antigen [36]. Immune complexes are predominantly cleared by the 
reticulo-endothelial system (RES) of liver and spleen by Fc-receptor binding and 
subsequent phagocytosis [36,37]. When the levels of circulating immune complexes is 
increased, immune complexes can also be found deposited in the extracellular matrix 
of several organs, including the glomerulus [38], lungs [39], skin [40] and blood 
vessels [41]. Under normal circumstances, such immune complexes are rapidly and 
effectively cleared, as evidenced by experimental injection of large amounts of 
immune complexes [42], but retainment can trigger local inflammatory disease, such 
as is the case in vasculitides and glomerulonephritides. The dynamics of immune 
complex formation and its deposition within tissues are topics of great interest in SLE 
research, as they are considered a key mediator of end-organ disease. 
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4.3.3 Animal models for the study of SLE 
SLE is not strictly a human disease, and is known to occur spontaneously in animals, 
especially in dogs, where the incidence is considerable [43]. For practical reasons, 
mice have become the preferred subject of studies of SLE. The most extensively 
studied model of spontaneously developing SLE-like disease is the F1 crossbreed 
progeny of the highly inbred mice New Zealand Black (NZB) and New Zealand 
White, referred to as (NZBxNZW)F1. Whereas the parental strains can develop 
proteinuria and evidence of autoimmune disease at old age, their offspring 
consistently develop an autoimmune phenotype with anti-dsDNA autoantibodies, 
progressive lupus-like glomerulonephritis, splenomegaly and arthritis occurring at 
around 20-35 weeks of age, and eventually they die from end-stage renal failure or 
cardiovascular disease [44,45].  
 
4.4 Lupus nephritis 
4.4.1 General features of lupus nephritis 
In the early 1950s lupus nephritis was the main contributor to early death in SLE 
patients, with an estimated 5-year survival rate of 25-40% following the diagnosis of 
nephritis [46]. Over the ensuing 35-40 years, advances in clinical medicine including 
cytostatic therapy, immunosuppressants, antihypertensive drugs and new antibiotics, 
as well as the introduction of dialysis and renal transplantation have resulted in a drop 
in 5-year mortality from LN to <10% [47]. Still, aggressive LN subtypes require high-
intensity immunosuppressive regimens and contribute considerably to the growing 
number of renal transplant recipients and patients requiring chronic dialysis, so the 
burden of disease and quality-of-life effects of lupus nephritis in SLE patients is still 
considerable.  
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Estimates of occurrence of the spectrum of renal disease in SLE patients vary 
from 35% to over 90% [48,49]. This likely reflects the great diversity in the clinical 
manifestations and disease severity of lupus nephritis. Whereas in most patients LN is 
limited to asymptomatic, self-limiting low-grade proteinuria (proteinuria is found in 
about 42% of SLE patients [50]), others progress towards end-stage renal failure in a 
matter of weeks to months, and respond poorly even to high-intensity 
immunosuppressive therapy. 
 There are several challenges in dealing with lupus nephritis. Firstly, clinical 
symptoms as well as laboratory findings have low predictive value in identifying 
patients at risk of developing severe renal disease. Monitoring of anti-dsDNA and 
other groups of autoantibodies has been proposed to serve as indicators of renal 
disease activity [51,52,53,54], but in general, their sensitivity and specificity are 
unsatisfactory, and their utility in clinical practice remains controversial. Evaluation 
of LN therefore generally requires histopathological examination of renal biopsies to 
establish the nature and extent of renal pathology, although the prognostic information 
provided by a kidney biopsy is limited by the fact that transformation of one 
morphological pattern to another occurs in 15 to 40% of patients during serial follow-
up [55,56,57]. The requirement for an invasive study such as a renal biopsy as part of 
initial and follow-up disease monitoring is largely impractical and carries 
considerable procedural risk, so there is a great interest in identifying useable markers 
of disease progression in LN. A number of assays in both serum and urine have been 





4.4.2 Classification of lupus nephritis 
Several systems of classification have been developed to categorize the complex and 
overlapping manifestations of lupus nephritis, taking into account both 
histopathological appearance, patterns of immune complex deposition as well as 
clinical presentation, progression and prognosis. 
The most common clinically used classification system today is that of the 
International Society of Nephrology and Renal Pathology Society (ISR/RPS) working 
group on the classification of lupus nephritis, which is periodically revised by a 
consensus meeting, the latest revision undertaken in 2003 [58] (Table 1). This system 
divides LN into six major classes, with the dominating pattern of cellular proliferation 
and matrix expansion being the defining characteristic. Also, the pattern of glomerular 
immune complex deposition, as visible by direct immunofluorescence (DIF) and 
electron microscopy, differ between the classes. This classification system has proven 
valuable as a prognostic index, but is limited by a considerable overlap and 




Table 1 - Abbreviated International Society of Nephrology/Renal Pathology 
Society (ISN/RPS) classification of lupus nephritis (2003) 
 Class I  Minimal mesangial lupus nephritis 
 Class II  Mesangial proliferative lupus nephritis 
 Class III  Focal lupus nephritis 
 Class IV  Diffuse segmental (IV-S) or global (IV-G) lupus nephritis   
 Class V  Membranous lupus nephritis 
 Class VI  Advanced sclerosing lupus nephritis 
!
"#$%&'#!()*+!Weening et al. (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J 
Am Soc Nephrol 15: 241-250.!
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Generally speaking, class I- and II changes are considered mild renal disease, and 
rarely progress to renal failure in humans, whereas classes III and IV are the subtypes 
classically associated with rapidly progressive glomerular damage. Class V has a 
lower rate of progression to end-stage renal disease, but is associated with an 
increased occurrence of thromboembolic diseases. Class VI is characterized 
widespread glomerulosclerosis in the absence of active inflammatory activity, and 
represents the end stage healing process following burned-out chronic or acute forms 
of nephritis. 
 
4.4.3 Pathogenesis of lupus nephritis 
Lupus nephritis is characterized by the appearance of immune complex deposits along 
glomerular membranes and within the mesangium. These immune complexes 
typically consist of DNA-anti-dsDNA aggregates, but other antigens are localized to 
these regions as well, including nucleosomal chromatin, histones, complement factor 
C1q, Sm, SSA/SSB, ubiquitin and ribosomal proteins [59]. The site of origin of these 
immune complexes is a matter of controversy. The proposed mechanisms for their 
appearance include in situ formation by binding of circulating autoantibodies to 
membrane-bound antigens or “trapping” of circulating immune complexes either 
passively or by affinity of the immune complex antigens against extracellular 
membrane components, as discussed in [60,61]. Regardless of the mechanism of their 
appearance, it is clear that the pathological effects of immune complexes are largely 
affected by their localization within the glomerulus. This is reflected in the extensive 
classification system needed to encompass the various faces of lupus nephritis.  
 Mesangial and subendothelial immune complex deposits are in contact with 
the vascular compartment, allowing for complement activation and consequent 
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chemokine release and influx of inflammatory cells. This leads to cellular 
proliferation with generation of active urinary sediments, proteinuria and often-rapid 
progression towards end-stage renal failure. In contrast, in patients with 
membranoproliferative disease (Class III/IV), biopsies show evidence of sub-
epithelial immune complex deposits separated from the vasculature by the glomerular 
basement membrane (GBM). This prevents the release of chemoattractant proteins 
into the circulation. Patients with such deposits therefore present with proteinuria 
without signs of active sediments, and biopsies show histological signs of 
membranous nephropathy, with a diffusely thickened GBM but little evidence of 
cellular proliferation or inflammatory cell infiltrates (Class V). 
 
4.4.4 Glomerular extracellular membranes and matrices in lupus nephritis 
Apparent expansion and structural changes in the glomerular extracellular membranes 
can be seen even in patients with mild forms of lupus nephritis (Class I/II). The key 
importance of the site(s) of immune complex deposition for the clinical 
manifestations of lupus nephritis has led to an interest in understanding the 
interactions between immune complexes and the GBM. Moreover, the structural 
changes occurring within this highly specialized barrier are thought to be important in 
the formation of a dysfunctional glomerular filtration system and the development of 
proteinuria. 
The term GBM refers to the extracellular matrix (ECM) interface that separates the 
endothelial cells of the glomerular capillary lumen and the podocytes that line the 
visceral side of the capsular space (Bowman’s space), as illustrated in Figure 1. In 
addition to the GBM, the glomerulus contains a more extensive mesangial 
extracellular matrix that branches out throughout the interstitial space of the 
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glomerular corpuscle. Not a part of the glomerular filtration barrier, this membrane is 
less specialized than the GBM, but is nonetheless a common location for immune 
complex deposits. The term “glomerular extracellular membranes” is therefore used 
herein to include both the GBM and the mesangial matrix.  
 The glomerular extracellular membranes are composed of a number of 
proteins, including collagen, heparan sulphate proteoglycans (HSPG), laminins, and 
fibronectin [62,63]. These form a complex meshwork that serves a number of 
purposes including the provision of mechanical strength of tissue compartments, 
sequestration of signaling substances and matrix-cell interactions involved in 









The GBM is characterized by the presence of particular subsets of collagen IV 
molecules which are thought to be important for its functions in ultrafiltration [65]. 
Histological and immunohistochemical analyses have indicated that the collagen IV 
matrix expands during the development of lupus nephritis, but it is unknown whether 
this reflects increased accumulation of collagen or structural changes that alter the 
appearance of the membrane. Previous experiments in our group have shown a 
considerable affinity of chromatin particles to extracellular matrix proteins, including 
collagen IV [66], suggesting that ECM structure may influence the tendency for 
immune complexes to accumulate within glomerular membranes. It would seem 
possible that increased availability of collagen IV and alterations in the structural 
integrity of the collagen matrix could contribute to immune complex deposition 
during disease progression. 
Collagen IV is secreted as monomers that join end-to-end, forming long 
fibrillary chains. Cross binding of fibrils generates a tightly woven collagen network. 
The collagen IV monomers are composed by three intertwining chains, of which there 
are six varieties, named collagen IV !1 through !6. Various triplet combinations 
form different collagen IV isomers, which have different properties in terms of tissue 
distribution and biophysical properties [67]. The biological importance of various 
collagen IV isoforms is well illustrated by hereditary glomerulopathies such as Alport 
syndrome, in which nonsense mutation of the col4a3 gene, encoding the !3 chain of 
collagen IV, prevents the expression of the collagen IV isoform !3!4!5 within the 
GBM [68]. These patients have a thickened and dysfunctional GBM and develop 
proteinuria progressing to end-stage renal disease [69,70]. 
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4.4.5 Matrix metalloproteinases in extracellular membrane turnover 
The proper structure and functioning of extracellular matrices relies on its constant 
renewal, and homeostasis is achieved by balancing synthesis of membrane 
components and their destruction by various secreted proteases. The enzymes 
responsible for membrane degradation include members of the serine and threonine 
proteinases families and the matrix metalloproteinases (MMPs). The MMP family of 
proteinases encompasses over 20 different divalent cation-dependent enzymes with 
diverse and overlapping substrate specificities (an updated list of substrates is 
available at the Overall lab webpage [71]). Of these, MMP-2 and -9 (referred to as 
the gelatinases) are notable for their affinity for collagen IV, and has therefore been a 
focus of the current work. A schematic overview of their structure is shown in Figure 








A more comprehensive review of the structure and functions of the gelatinases and a 
discussion of their relevance to various renal pathologies including lupus nephritis 
[72] has been included as an appendix (Appendix 2).  
Within the glomerulus, MMP-2 appears to be the predominant gelatinase in 
healthy individuals, showing constitutive expression in both mesangial cells and 
podocytes [73]. MMP-9 expression, on the other hand, appears to be induced by 
various pro-inflammatory signaling cascades under circumstances of tissue injury, 
especially in mesangial cells. MMP-9 is also expressed in activated infiltrating 
macrophages/monocytes in inflammatory states [74,75]. MMP enzyme activity is 
negatively regulated by tissue inhibitors of metalloproteinases (TIMP) 1-4. The 
MMP/TIMP ratio is therefore essential in regulating net MMP activity in vivo, 
although this view is somewhat simplistic, as reviewed in [72].  
Gene expression analyses have indicated increased expression of MMP-2 and MMP-9 
in both human and murine lupus nephritis [76,77], but similar increases in expression 
of several of the TIMPs complicates the picture [78,79,80], and the net effects on 
gelatinase activity remains uncertain. Also, the tissue distribution of MMP and TIMP 
expression within the kidney in lupus nephritis is undetermined.  
 
4.5 Wnt signaling 
Amongst the cellular signaling pathways known to affect the synthesis and turnover 
of extracellular matrices, Wnt-signaling has recently been found to play a role in the 
development of proteinuria [81] and renal fibrosis [82] in several animal models. 
Emerging evidence suggest that activation of Wnt signaling may induce synthesis of 
both matrix metalloproteinases [83] and various ECM constituents, including 
collagens and fibronectin [82]. These data makes renal Wnt signaling a potentially 
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important element in understanding the alterations in the glomerular extracellular 
milieu occurring as part of the pathogenesis of glomerulonephritis. 
 The Wnt pathway is a signaling pathway is found to be highly conserved 
within a wide number of organisms. Originally identified to be involved in 
embryogenesis, it has recently been discovered that Wnt signaling also influences 
adult tissue homeostasis, and it has been implicated in several human diseases, 
especially malignant diseases, where it seems to be important in regulating cancer 
growth and metastasis. 
With growing insight into the complexity of Wnt signaling, it is apparent that the Wnt 
pathway branches out to at least three downstream cascades. The following sections 
will focus entirely on what is referred to as the canonical Wnt/beta-catenin pathway, 
as this has been the topic of studies in the present work. Suffice it to mention, 
therefore, that Wnt signaling also includes the non-canonical Jun kinase and Wnt/Ca2+ 
pathways [84]. Furthermore, there is widespread crosstalk between all branches of 
Wnt signaling and other pathways, an insight that is continuously expanding. 
 The Wnt/beta-catenin pathway is activated through binding of one of the many 
secreted Wnt proteins (Wnt1-11 and Wnt16) to transmembrane receptors of the 
Frizzled or Lipoprotein receptor-related protein (LRP) families. Activation of these 
receptors induces dephosphorylation of the transcription factor beta-catenin [85]. This 
enables beta-catenin to translocate to the nucleus, allowing it to form a complex with 
T-cell factor (TCF) to activate the transcription of a number of Wnt target genes. The 
activity of the Wnt pathway is modulated by a multiprotein complex consisting of 
glycogen synthase kinase 3 (GSK3b), Axin and the tumor suppressor gene 
adenomatous polyposis coli (APC). This complex phosphorylates beta-catenin, 
targeting it for proteosomal destruction, as illustrated in Figure 3.  
! 19!
 
In addition, Wnt signaling activity can be modulated by secreted Wnt antagonists, 
which include the Dickkopf (Dkk) family of proteins, secreted Frizzled proteins 
(sFRPs), Wnt inhibitory factor (WIF-1) and Soggy [85]. The DKK proteins bind to 
LPR5/6, preventing interaction with Wnt/Frizzled complexes, and promote 
internalization of the LPR receptors. Dkk-1 serves as a direct inhibitor of the 
Wnt/beta-catenin pathway [86], whereas the effects of Dkk-2/-3 are less clear. The 
sFRPs and WIF-1 work by binding to Wnt proteins, preventing their binding to 
Frizzled receptors. sFRPs can also form inhibitory complexes with Frizzled receptors 
(reviewed in [85]).  
 In unstimulated cells, beta-catenin is rapidly degraded through the 
proteosomal apparatus. In adult human tissues, constitutive Wnt signaling activity is 
generally low, with the notable exception of tissue stem cells. In recent years, 
Figure 3 
!
From Staal et al., Nat Rev Immunol, 2008 vol. 8 (8) pp. 581-93!
i   
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however, it has been found that Wnt activity is increased during the course of several 
diseases. The growing list of diseases in which Wnt signaling has been implicated 
includes many types of cancer, neurologic diseases, bone, kidney and skin diseases, as 
reviewed in [87]. The involvement of the Wnt pathway in renal diseases was first 
discovered with the finding that mRNA expression of the Wnt agonist Wnt4a was 
highly increased in experimental unilateral uretheral obstruction (UUO) [88], a rat 
model of obstructive uropathy. In the same model, suppression of Wnt signaling by 
injection of recombinant sFRP4 [89] or Dkk-1 [82] appeared to attenuate progression 
of renal fibrosis. Similarly, modulation of glomerular Wnt signaling has been found to 
affect the progression of various forms of glomerulopathies. Studies have shown that 
glomerular damage and subsequent development of proteinuria induced by 
adriamycin could be strongly attenuated by suppression of beta-catenin expression 
[81]. In contrast, diabetic nephropathy in rats is associated with a Dkk-1-mediated 
reduction in Wnt pathway activity, and preserving Wnt signaling yielded favorable 
results in this model [90]. These conflicting results demonstrate that the effects of 
renal Wnt signaling are not clear-cut. One possible explanation could be the different 
nature of these diseases; the former representing an acute inflammatory 
glomerulopathy, whereas the latter constitutes a chronic process dominated by fibrosis 
rather than inflammation. Similar differences are apparent when analyzing the 
consequences of altered matrix metalloproteinase activity in various 
glomerulopathies, as discussed in [72]. 
From the perspective of SLE, another interesting aspect of Wnt signaling is its 
apparent involvement in apoptotic signaling. It appears that Wnt activation has anti-
apoptotic effects, at least in vitro, by increasing the threshold for induction of 
apoptosis by various stimuli [91]. Conversely, Dkk-1 serves as a pro-apoptotic factor 
! 21!
[92,93]. It remains a matter of controversy whether Dkk-1 can itself induce apoptosis. 
Work in immortalized cell lines and various cancer cell lines has found Dkk-1 to 
lower the threshold for apoptosis induced by other stimuli, but find no direct 
apoptosis-inducing effect [94,95]. In contrast, over-expression of Dkk-1 appeared to 
have direct apoptosis-inducing effects in hepatic stellate cells [96] and in a melanoma 
cell line [97]. The latter study found the apoptosis-inducing effect to be mediated 
through activation of c-Jun N-terminal kinase (JNK) rather than through the canonical 
Wnt/beta-catenin pathway. Similar results were also seen in placental 
choriocarcinoma [98]. A recent study in SLE patients found consistently increased 
serum levels of Dkk-1 compared to normal healthy controls, although no significant 
association was found between Dkk-1 concentration and commonly used serological 
or clinical disease indices [99]. Although these results are inconclusive with respect to 
the origin or consequences of the increase in circulating levels of Dkk-1, they provide 
clues to a potential role of alterations in Wnt signaling during the course of SLE.  
 
 
4.6 Deoxyribonucleases and autoimmune diseases 
Autoantibodies against double-stranded DNA (dsDNA) is considered a hallmark of 
SLE, and anti-dsDNA antibodies are reported to occur in about 75% of SLE patients 
at some point [100]. Numerous studies report autoantibodies against DNA and DNA-
containing particles (nucleosomes/chromatin) as a major constituent of glomerular 
immune complex deposits [101,102,103,104].  
 Previous studies have confirmed the presence of DNA and chromatin-
associated antigens in electron-dense structures at the ultrastructural (electron 
microscopy) level using both antibody-based and terminal deoxynucleotidyl 
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transferase dUTP nick end-labeling (TUNEL) methods [105,106]. Together, these 
studies provide basis for the assumption that chromatin structures form an important 
antigen target in SLE and in LN [107,108]. The occurrence of chromatin structures 
deposited within the GBM is a surprising finding, as chromatin degradation by 
endonucleases is a key event in the orderly process of apoptotic cell death 
[109,110,111], as discussed in section 4.3.1. By contrast, death by necrosis causes 
leakage of chromatin particles through a disrupted plasma membrane, and 
externalized chromatin serves as a potent danger signal, causing immunological 
activation of nearby antigen-presenting cells and induction of a pro-inflammatory 
response [112]. If apoptotic cells are not efficiently cleared, leakage of chromatin 
particles and secondary necrotic transformation is seen [113]. 
Increases in circulating DNA content is a common finding in a variety of 
inflammatory diseases, including trauma [114], myocardial infarction [115] and 
cancer [116]. How such circulating DNA is removed is not known, but it is assumed 
that secreted deoxyribonucleases (Dnases) play an important role. SLE patients have 
been reported to harbor higher levels of circulating DNA than the baseline population 
[117,118,119]. These DNA structures have been reported to be sizes corresponding to 
the expected sequence length of mono- and oligonucleosomes [120], which would 
seem to indicate that chromatin degradation products formed during cell death 
accumulate in the extracellular milieu in these patients, either as a result of massive 
cell death or faulty chromatin disposal [121,122]. At the same time, it has been known 
since the 1960s that serum Dnase activity is decreased in SLE patients [123]. 
Deoxyribonuclease 1 (Dnase1) was the first secreted Dnase to be identified in 
serum. The relative contributions of various tissues in the synthesis of circulating 
Dnase1 is unknown, although the gastrointestinal tract, kidneys, liver and spleen are 
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considered major sources [124]. Dnase1 appears to be responsible for the bulk of 
DNA degrading capacity within the circulation [125]. However, Dnase1-/- knockout 
mice showed evidence of residual Dnase activity that has been attributed to the 
enzyme Dnase1-like 3 (Dnase1L3, also known as Dnase gamma) [126]. To date, the 
list of known secreted endonucleases include Dnase1 as well as the Dnase1-like 
family (Dnase1L1 through -3). These proteins vary in tissue distribution, and their 
biological importance remains unclear. 
Based on the above-mentioned findings of decreased serum nuclease activity 
in SLE patients, there has been a great interest in disturbed function of Dnase1 as a 
potential mediator of extracellular chromatin accumulation, and possibly the 
emergence of antinuclear autoreactivity. Dnase1-deficient mice were found to 
produce anti-dsDNA and anti-nucleosomal antibodies, glomerular immune complex 
deposition and development of proteinuria [127]. Furthermore, a 2001 article reported 
the presence of a heterozygous Dnase1 non-sense mutation in two Japanese SLE-
patients displaying very high levels of anti-nucleosomal antibodies [128]. Reduced 
levels of Dnase1 has been observed in sera of SLE patients, with a inverse correlation 
between disease activity and serum Dnase1 activity [129]. The same is true for serum 
and urine Dnase1 activity in young (NZBxNZW)F1 mice [130].  
The origin of reduced Dnase1 activity in SLE patients has been a matter of 
controversy. Some authors have found circulating inhibitors of Dnase1, including 
glomerular actin [123] and neutralizing autoantibodies [131] to be responsible, 
whereas others have not been able to reproduce these results [129]. Of note however, 
many of these studies have been limited by their reliance on single non-specific in 
vitro assays of Dnase activity. Interpretations on alterations in Dnase1 activity are 
complicated by the currently limited knowledge of the factors controlling its 
!24!
expression, and as stated above, the existence of a family of incompletely 
characterized Dnase1-like enzymes with similar biochemical characteristics.  
 Despite the focus on Dnase1 activity in the circulation of SLE patients, little is 
known about its expression and activity within the tissues. A recent study of 
apoptosis-related gene expression in kidneys of B/W mice revealed a dramatic 
decrease in Dnase1 mRNA expression accompanying the development of proteinuria 
[132]. Follow-up studies revealed a close association between renal Dnase1 mRNA 
levels and the development of severe renal manifestations, including glomerular 
capillary immune complex deposits and histopathological changes consistent with 
membranoproliferative lupus nephritis [133], which suggest that renal Dnase1 may 
contribute to the progression of particular subsets of lupus nephritis.  
The association between the appearance of chromatin-associated immune 
complexes within the GBM and the apparent disappearance of an enzyme assumed to 
play a key role in eliminating extracellular chromatin offers an attractive hypothesis to 
explain how tissue-specific changes in gene expression could influence the pattern of 
immune complex deposition [134,135]. This also provides a potential link between 









5. AIMS OF THE THESIS 
• Investigate the mechanistic basis of apparent matrix expansion in developing 
lupus nephritis and its relevance to the formation of electron-dense structures 
(Paper I and II) 
 
• Characterize changes in collagen IV synthesis and turnover during the course 
of development of lupus nephritis in (NZBxNZW)F1 mice. 
(Paper II) 
 
• Identify proteases responsible for collagen degradation within the glomerulus 
in lupus nephritis. 
(Paper I and II) 
 
• Evaluate location, expression and activity of the major renal endonuclease 
Dnase 1 in kidneys during the development of nephritis. 
(Paper III) 
 
• Assay the regulation of the canonical Wnt pathway in lupus development, and 





6. MATERIAL AND METHODS 
6.1 Animals and tissue collection 
All experiments were approved by the Norwegian Ethical and Welfare Board for 
Research Animals. Female BALB/c and B/W mice were used, and urinary dipstick 
analyses were obtained on a weekly basis to monitor the development of proteinuria. 
Animals were euthanized by CO2 suffocation at the age of 4, 8, and 20 weeks or upon 
development of proteinuria (3/4+ on dipstick, corresponding to >300mg/dL). 
Terminal blood samples collected from the heart were used to prepare sera. Kidneys 
were immediately extirpated, sliced, and preserved in RNAlater!, fixed in 4% 
paraformaldehyde or McDowell’s fixative for morphological studies by electron 
microscopy, snap-frozen in liquid N2 for protein extraction, or embedded in optimal 




Indirect immunofluorescence studies were performed using freshly prepared non-
fixated cryosections. Negative controls included omission of primary antibody and 
assays using total serum IgG from the relevant species in concentrations 
corresponding to that of the antibody in question. For all assays, identical 
magnification and exposure settings were used for all slides. 
 
6.3 RNA isolation, cDNA synthesis and realtime-PCR analysis 
Upon collection, tissues were immediately placed in RNALater! (Ambion Inc, 
Austin, TX) preservation solution to prevent RNA degradation upon storage. RNA 
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isolation from tissues was performed using a commercially available kit (EZ1 RNA 
Tissue mini kit; Qiagen, Hilden, Germany). For cell culture experiments, a Trizol!-
based isolation protocol (Ambion) was utilized. RNA concentration and purity was 
verified using spectrophotometrical methods, and cDNA synthesis was done using 
equal amounts of RNA for all samples. Realtime PCR was performed using the !!Ct 
method, in which the amplification threshold is normalized against that of a reference 
gene that is assumed to be stably expressed in all cells (a so-called housekeeping 
gene). The selection of housekeeping genes for the realtime PCR studies was done 
based on absolute quantification assays for a number of candidate genes. 
Commercially available, pre-designed TaqMan! primer/probesets (Applied 
Biosystems) were utilized for all the assayed genes. 
 
6.4 Gel zymography 
Gel zymography is a classic method to measure enzymatic activity from a tissue 
sample in vitro. Protein samples are electrophoretically separated on a sodium 
dodecyl sulphate (SDS) polyacrylamide gel that contains a substrate for the enzyme(s) 
to be studied. The SDS is then washed out of the gel with 2% (v/v) Triton X-100 in 
water, allowing for (partial) renaturing of the proteins. Incubation of the gel under 
optimized conditions in the presence of required co-factors then allows for the 
enzymatic breakdown of the substrate. After incubation, visualization of remaining 
substrate allows for the identification of areas of degradation. This provides 
information about the molecular weight of the responsible enzymes, and their relative 
contribution to substrate degradation. By comparison with purified enzyme 
preparations, estimates of absolute enzyme concentrations can also be made. The 
inclusion of various inhibitors to the reaction mixture during incubation allows for 
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further identification of the responsible enzymes. 
For gelatinase zymography, gelatin was added to the gel, and the gel developed by 
Coomassie blue staining, which colors areas of high protein content. For Dnase 
zymography, salmon sperm DNA fragments were added to the gel, and the gel 
developed by ethidium bromide staining, which intercalates with DNA, allowing 
visualization of areas containing DNA under ultraviolet transillumination. Areas of 
reduced ethidium bromide staining indicated the concentration and molecular weight 
of active nucleases within the samples. 
 
6.5 In situ zymography 
The activity of enzymes in vitro is influenced by a multitude of factors, including the 
presence of other peptide, electrolytes and pH. Such influences are eliminated when 
employing gel-based enzymatic assays. Also, information about the distribution of 
active enzyme within the tissue is missed. To be able to obtain some of this 
information, in situ enzymatic assays were utilized for both collagen-degrading and 
DNA-degrading activity. 
For the assay of collagen-degrading activity, a previous protocol was adapted[136], in 
which kidney cryosections were overlaid with a fluorescently labeled gelatin substrate 
and incubated with a reaction mixture at 37°C in the dark. In its native form, 
fluorescence in this substrate is quenched, but is detectable by fluorescence 
microscopy upon proteolytic degradation. Thus, areas of fluorescence correspond to 
areas of gelatinolytic activity. By adding various inhibitory substances to the gelatin 
substrate, the nature of the responsible enzymes could be further pinpointed. 
A similar assay was developed for the in situ detection of DNA-degrading activity in 
kidneys. This method utilized a terminal deoxynucleotidyl transferase (TdT) DNA 
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fragmentation detection kit. TdT is a DNA polymerase that adds nucleotides to the 3’ 
end of DNA fragments. By introducing fluorescently labeled nucleotides, incubation 
of sections with TdT allows for the visualization of DNA fragmentation within cells. 
Freshly prepared kidney cryosection were incubated with a Dnase activation buffer at 
37°C. After the incubation, TdT-based labeling of DNA fragments was performed. 
Areas with nuclease activity were thus visualized as fluorescent dots by fluorescence 
microscopy, with fluorescence intensity reflecting relative nuclease activity in the 
sections being compared. 
 
6.6 Radial diffusion nuclease activity assay 
To take into account the effects on total Dnase activity of various inhibitory 
substances present in tissue samples, a previously developed radial diffusion assay 
was utilized for studies of DNA-degrading activity in kidney and serum samples[125]. 
Briefly, gels containing DNA were spotted with 1µL of the samples to be analyzed. 
Serum was spotted directly into wells in the gel. For protein extracts, total protein 
concentration was determined by bicinchoninic acid assay (BCA assay; Pierce 
Biotechnology, Rockford, IL), and normalized protein sample aliquots added to the 
gel. Upon incubation at 37°C, remaining DNA within the gels was visualized by 
ethidium bromide staining. By measuring the areas of loss of DNA staining and 
comparing these to recombinant Dnase1 standards, an index was obtained for DNA-







7. SUMMARY OF THE PAPERS 
7.1 Paper I 
Kidneys from female (NZBxNZW)F1 mice were collected at ages 4, 8 and 20 weeks 
and at the time of development of significant (>300 mg/d) proteinuria. Kidneys from 
age-matched BALB/c mice were used as controls. 
By covering freshly prepared cryosections with a fluorescent collagen substrate, 
increased net collagenolytic activity was seen in proteinuric stage B/W kidneys. Gel 
zymography identified collagenolytic bands corresponding in size to MMP-2 and 
MMP-9. These collagen-degrading proteases were efficiently inhibited by EDTA, 
while serine protease inhibitors had no effect. 
Real-time PCR demonstrated a dramatic increase in MMP-2 expression at the 
proteinuric stage, with a more modest increase for MMP-9. Immunofluorescence 
studies of sections showed strong glomerular staining for both MMP-2 and MMP-9 in 
proteinuric B/W mice. Furthermore, glomerular expression of the MMP9-stabilizing 
protein lipocalin-2 was also increased at proteinuria, providing an explanation for the 
abundance of MMP-9 in zymography studies. 
Real-time PCR analysis of collagen IV expression, one of the major glomerular ECM 
constituents and an MMP-2/MMP-9 substrate, showed unchanged expression levels 
for the normal ECM isoform (!3!4!5) of this protein during disease progression. 
However, expression of other collagen IV alpha chains (!1, !2 and !6) was increased 
at the proteinuric stage, possibly indicating alternative collagen IV isoform being 





7.2 Paper II 
Based on previous data indicative of altered collagen IV expression in proteinuric 
B/W kidneys, immunofluorescence studies were performed using collagen IV alpha-
chain-specific antibodies. Increased staining was seen for both !1 and !2, suggesting 
increased expression of the collagen IV isoform !1!1!2 within the glomerular 
basement membrane (GBM). Also, an isoform containing !6, normally confined to 
Bowman’s capsule, was also detectable in proteinuric stage GBM. These results are in 
accordance with previous results by real-time PCR.  
 Increased expression of the MMP-like protease A disintegrin and 
metalloproteinase domain-containing protein 15 (ADAM-15) was demonstrable in the 
glomeruli of proteinuric stage mice, complementing previous findings of increased 
MMP-2 and MMP-9 activity in these mice. In vitro digestion by incubation of renal 
cryosections with recombinant forms of MMP-2 and -9 verified that the aberrant, 













7.3 Paper III 
Previous studies have shown DNA and several DNA-associated proteins to be present 
in regions of immune-complex deposits within glomerular basement membranes 
(GBM). This suggests that deposited autoantibodies are associated with retained 
extracellular chromatin particles. The major secreted DNA degrading enzyme in 
humans and rodents is Dnase1, and serum activity of this enzyme has been reported to 
be decreased in serum from SLE patients. Previous real-time PCR analyses revealed a 
dramatic decrease in the expression of Dnase1 in proteinuric stage B/W mice [132], 
which appears to correlate with the development of GBM-associated immune 
complexes and histological changes resemblant of membranoproliferative lupus 
nephritis [133]. To substantiate these findings, we confirmed that these changes were 
paralleled by decreased Dnase1 protein levels, and that these changes translated to 
decreased DNA-degrading activity by in situ and zymographic methods. In line with 
previous data, decreased Dnase1 expression was seen only in mice with histologically 
severe lupus nephritis with immune complex deposition within the GBM, whereas 
mice with milder nephritis and a mesangial pattern of immune complex deposition 
had near-normal levels of renal Dnase1. Immunofluorescence studies of biopsies from 
patients with lupus nephritis gave similar results, with decreased staining for Dnase1 
found only in patients with membranoproliferative nephritis. 
Serum levels of Dnase1 activity dropped at around the same time as within the 






7.4 Paper IV 
Based on recent data supportive of a role of the canonical Wnt/beta-catenin pathway 
in the regulation of renal extracellular matrix turnover, expression of this signaling 
pathway was assayed in kidneys of (NZBxNZW)F1 mice during development of 
lupus nephritis.  
A strong increase in the expression of Wnt-responsive genes was seen within the 
kidney from around the time of appearance of anti-dsDNA autoantibodies, also 
reflected in increased levels of the activated form of beta-catenin. At the same time, 
serum from these mice had an inhibitory effect on Wnt signaling in mesangial cells in 
vitro. Sera from 20-week old and proteinuric (NZBxNZW)F1 mice contained high 
concentrations of the Wnt inhibitor Dkk-1. In accordance with previous reports, Dkk-
1 in the concentration range seen in lupus sera had a strong apoptosis-inducing effect 











8.1 Extracellular membrane changes in lupus nephritis 
The glomerular basement membrane constitutes a highly specialized extracellular 
matrix that provides a physical and electrochemical filtration barrier, and its patency 
is ensured by a constant process of renewal. Under circumstances of increased stress 
and tissue damage, compensatory mechanisms are activated which alter membrane 
properties in more or less beneficial ways. These changes include altered kinetics of 
membrane synthesis/turnover, as well as fibrotic changes by activation of 
undifferentiated mesenchymal cells. Our interest in the collagen matrix stems from 
the finding that the nucleosomes that form an abundant element of glomerular 
immune complex deposits show high affinity towards collagen IV and laminin [66]. 
Alterations in the composition and abundance of this matrix could therefore be 
important in understanding the formation and localization of immune complexes in 
lupus nephritis. 
Previous studies using immunohistochemical methods have indicated that the 
collagen IV matrix is thickened in patients with lupus nephritis. Using messenger 
RNA (mRNA) expression data and isoform-specific antibodies, we have found 
evidence demonstrating that qualitative changes in collagen IV matrix composition 
take place in nephritic stage B/W mice. Collagen IV !1!1!2 represents an isoform 
that is seen during embryonic kidney development, and is located within the 
mesangial matrix [137]. It seems likely that the abundance of this isoform within 
nephritic glomerular membranes may represent a compensatory switch in matrix 
synthesis due to increased matrix turnover that serves to preserve matrix patency. A 
similar isoform switch is seen in Alport syndrome, where a mutation prevents the 
synthesis of the !3!4!5 isoform that typifies the GBM [69]. Interestingly, this leads 
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to the development of an irregular, leaky membrane similar to that seen in patients 
with lupus nephritis. The occurrence of col4a6 within the GBM is surprising, as this 
type of collagen IV chain is normally only present within the parietal aspect of 
Bowman’s capsule. The only known collagen IV isoform known to include col4a6 is 
the !5!5!6, the mechanical and biochemical properties of which are largely 
unknown.  
 The relative affinity of various collagen IV isoforms for immune complex 
constituents including nucleosomes is unknown. It is possible that qualitative changes 
in the composition of glomerular extracellular membranes occurring as a consequence 
of tissue injury could increase the binding of chromatin-associated antigens or 
chromatin-containing immune complexes.  
Based on their specificity for collagen IV, MMP2 and MMP9 (referred to as 
the gelatinases) constitute potentially important regulators of glomerular collagen IV 
matrix turnover. Indeed, gel zymography revealed that these proteins were responsible 
for the bulk of collagen IV-degrading activity in kidneys. Our studies revealed an 
increase in expression and in situ activity of both MMP-2 and -9 in proteinuric stage 
mice. Intuitively, these results may seem surprising, given the apparent expansion of 
the collagen matrix found in mice with lupus nephritis.  
Several reports have been published showing strong glomerular collagen IV 
immunostaining in both mice and patients with LN. However, no quantitative 
determination of glomerular collagen IV content has been made, and the assumption 
that increased immunostaining translates to increased expression therefore remains 
uncertain. What is clear, however, is that the distribution of collagen IV is altered 
during LN development, and that collagen IV forms a part of the apparently expanded 
extracellular matrix in affected glomeruli. 
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Expression of MMP-9 is known to be induced by pro-inflammatory signaling 
cascades, including activation of toll-like receptor 9 (TLR-9) [138,139]. Deposited 
anti-dsDNA-antibody-containing immune complexes causes inflammation by a 
number of mechanisms, including activation of the complement system, as well as 
activation of phagocytosing cells through toll-like receptors, including TLR9 [140]. 
The observed increase in MMP activity could stem from such pro-inflammatory 
stimuli affecting resident cells or infiltrating leukocytes. Although a detailed 
assessment of the origin of glomerular MMP expression was not performed, the 
widespread distribution of MMP immunostaining throughout the glomerular 
compartment suggests that several cell types are likely involved. Indeed, both 
mesangial cells and podocytes have been shown to produce MMP-2 and MMP-9 in 
vitro [73,141,142]. 
MMP-2 and -9 have been implicated in the progression of several types of 
glomerulopathies, as part of the pathophysiological process in both sclerotic and 
inflammatory diseases, as reviewed in [72,143]. MMP inhibitory studies in various 
glomerulopathies have yielded very different results, demonstrating that MMPs serves 
different functions in various disease states [144]. In general, it appears that activation 
of MMPs has detrimental effects in the context of inflammation by causing excessive 
membrane degradation, whereas in fibrotic processes, MMPs limit the expansion of 
the membranes by compensatory deposition of endogenous and aberrant ECM 
components [143,145]. This is complicated by the fact that the progression of many 
inflammatory glomerulopathies includes an initial phase of inflammatory tissue 
damage, followed by a fibrotic process of regeneration that leads to 
glomerulosclerosis. The effects of strategies to modulate MMP activity are therefore 
likely to be highly dependent upon the stage of tissue injury. Nonetheless, inhibition 
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of gelatinase activity during the active stages of experimental inflammatory 
glomerulopathies has yielded significant attenuation of tissue injury [146]. These 
results warrant evaluation of the effects of MMP inhibitory strategies in active forms 
of lupus nephritis, including correlation of MMP activity to histological subsets of 
LN. Indeed, recent data from our group indicates a correlation between increased 
mRNA expression of MMP-2 and the development of membranoproliferative LN 
[133]. Likewise, urinary concentration of the MMP-9-stabilizing protein lipocalin-2 
has recently emerged as an attractive biomarker for inflammatory renal damage 
[147,148]. 
 
8.2 Acquired loss of renal Dnase1 activity 
Our interest in renal Dnase1 activity was founded on recent findings in our group 
demonstrating that renal Dnase1 mRNA expression and enzyme activity levels were 
significantly decreased in mice showing signs of lupus nephritis [132,133,149], and 
that reduced Dnase1 gene expression correlated with the appearance of GBM-
associated immune complex deposits, consistent with of the pattern seen in 
membranoproliferative lupus nephritis [133]. Existing data has led to considerable 
controversy regarding the mechanism(s) underlying loss of serum Dnase1 activity in 
SLE patients, as discussed above. A detailed assessment of the various modes of 
Dnase1 regulation was therefore needed to identify the mechanism underlying the 
observed loss of renal Dnase1 activity. By including both gel-based, in situ and radial 
diffusion methods, we were able to assay Dnase activity both in crude extracts and 
after electrophoretical separation. Controlled pre-heating of samples to 56°C has been 
reported to reverse inhibition of Dnase1 by actin [123]. In our hands, such 
pretreatment did indeed increase total Dnase activity by radial diffusion, but did not 
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affect the relative difference in serum or renal Dnase activity between the groups, 
suggesting that in vivo inhibition by actin does not explain the observed difference in 
neither serum nor renal Dnase activity. Similarly, no differences were observed 
between radial diffusion and gel zymography assays, which further suggests that 
inhibition of serum Dnase1 by actin is not a major contributor to decreased serum or 
renal Dnase activity in B/W mice [150]. While not in agreement with the original 
findings by Frost and Lachmann in SLE patients, similar results have been reported 
by other groups [129]. 
The temporal relationship between the decrease in serum Dnase1 activity and 
the occurrence of anti-dsDNA autoantibodies does not favor a role for Dnase1 in the 
initiation of autoreactivity. Although decreased serum Dnase1 is a common finding in 
SLE patients, no correlation has been found between Dnase activity and disease 
activity indices or serological markers of disease activity [151]. However, an 
association was seen between low serum Dnase activity and the occurrence of active 
type III/IV nephropathy [152].  
The data presented in paper III demonstrates a decrease in mRNA and protein 
level expression of Dnase1 in kidneys of mice with evidence of immune complex 
deposits within the GBM, whereas mice with immune complexes confined to the 
mesangial compartment have renal Dnase1 expression comparable to that of normal 
BALB/c mice. In contrast, all the proteinuric mice had similarly decreased serum 
Dnase1 activity, irrespective of the pattern of immune complex deposition. This 
discrepancy between serum and kidney Dnase1 levels suggests that the changes 
observed in the renal compartment are due to changes occurring within the kidney. 
The mechanisms controlling the expression of Dnase1 are poorly understood. 
Our data suggest a uniform down-regulation of Dnase1 mRNA expression affecting 
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both the tubular and glomerular compartments. Identifying the means by which 
mRNA expression is shut down will be important in devising strategies to restore 
renal Dnase1 expression, and is the topic of ongoing investigations. Based on the 
apparent importance of Dnase1 in extracellular DNA degradation, such an 
intervention could potentially contribute in removing extracellular chromatin, thus 
preventing exposure of an immunogenic nuclear antigen, and possibly prevent 
deposition of glomerular immune complexes containing DNA/chromatin. 
 
8.3 Wnt signaling in lupus 
Current knowledge of the roles of the Wnt pathway in the post-embryonic stage in 
mammals is limited. The basis for our interest in this pathway was the recent 
discovery that activation of renal Wnt/beta-catenin signaling appears to be implicated 
in the development of adriamycin-induced glomerulopathy [81], and its apparent roles 
in the regulation of extracellular matrix homeostasis [153,154,155].  
 Our results revealed increased expression of Wnt target genes within the 
kidney despite a net Wnt inhibitory effect of serum from the same mice, at least in 
vitro. These findings are suggestive of local Wnt agonists serving as the predominant 
regulators of renal Wnt activity in vivo, and further identification of such factors is the 
topic of ongoing investigations in our group. 
Levels of active beta-catenin were increased both in glomeruli and tubular 
cells, suggestive of global alterations in renal Wnt activity, although the increase in 
immunostaining was most pronounced within the glomerular compartment. Similarly, 
expression of the Wnt inhibitor Dkk-1, itself a Wnt-induced gene [156], was found to 
be increased in both tubuli and glomeruli. It is apparent that the increase in renal Dkk-
1 expression is not sufficient to prevent a net increase in Wnt signaling during the 
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development of nephritis, although it might serve as a feedback mechanism to limit 
activation of the Wnt pathway, as previously suggested [156]. As discussed below, it 
is also possible that increased renal Dkk-1 expression could reflect activation of pro-
apoptotic signaling pathways as a result of increased cellular stress imposed by an 
inflammatory response. At any rate, the significant increase in renal Dkk-1 offers a 
potential explanation of the observed increase in serum Dkk-1 levels, which appears 
to occur at about the same time. Evaluating the interdependence of renal Wnt 
signaling and Dkk-1 levels, as well as the relationship between renal and serum levels 
of Dkk-1 will likely require experimental manipulation of renal Wnt signaling in vivo.  
 Dkk-1 has previously been identified as an apoptosis-promoting factor in 
various cell lines in vitro, although as mentioned above, controversy exists on the 
matter of whether it can by itself induce apoptosis. More importantly, the in vivo 
consequences of increased levels of Dkk-1 have not been assessed. Our data show an 
apoptosis-inducing effect of recombinant Dkk-1 on mesangial and tubular cells when 
cultured in vitro. These primary cell lines have stringent growth requirements, and it 
is therefore possible that the composition of growth media and/or supplements 
constitute cellular stress factors that render the cells more susceptible to apoptosis 
than would be the case in vivo, thus sensitizing the cells to the effects of Dkk-1. 
Nonetheless, the findings of increased levels of serum Dkk-1 in B/W mice, and the 
similar increase recently reported in SLE patients [99] suggest that Dkk-1 might 
indeed be a contributing factor to the increased levels of circulating apoptotic cells 
seen in SLE patients [30,31]. Moreover, it has been found that Dkk-1 is induced upon 
activation of pro-apoptotic pathways through p53 [157]. It is therefore also possible 
that increased serum Dkk-1 is a consequence rather than a cause for increased 
apoptotic cell load. Further clarification of these issues could be attained by 
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simultaneous monitoring of apoptotic cell load and serum Dkk-1 in vivo, and possibly 
by in vivo experiments utilizing the recently developed neutralizing antibodies against 
Dkk-1 [158].  
 
8.4 An integrated model of immune complex deposition and progression of 
nephritis? 
It seems clear that the inflammatory changes occurring during LN development is 
largely mediated by the deposition of immune complexes within glomerular 
membranes. T-cell mediated glomerular damage, reflected by increased T-cell influx 
in LN might represent an additional pathogenetic factor [159], but less is known about 
this cell-mediated aspect of tissue damage [160].  
IC deposition triggers classical type III hypersensitivity reactions by the engagement 
of the complement system. Type II reactions might also be involved through 
autoantibodies reacting or cross-reacting with various ECM components. The 
characteristic ICs of lupus nephritis consist of anti-dsDNA/anti-nucleosome 
autoantibodies complexed with chromatin-associated antigens [161,162,163]. 
Although the nature and origin of such complexes remain unknown, it is tempting to 
speculate that they represent retained extracellular chromatin fragments released 
during cell death [134], which is consistent with current hypotheses of impaired 
apoptotic cell clearance as a pathogenetic factor in SLE [32]. This chromatin could 
originate from the glomerulus itself, or be deposited from the circulation [108]. 
Indeed, both serum and renal Dnase1 activity was found to be decreased in mice 
showing evidence of such deposits. Of note, however, mice with ICs confined to the 
mesangium showed normal renal Dnase1 activity, suggesting that serum and renal 
Dnase1 may affect renal disease in different ways. It is tempting to speculate that 
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restoring renal DNase1 activity or otherwise facilitating elimination of membrane-
bound chromatin-containing ICs could serve as a therapeutic means of preventing the 
formation of glomerular inflammatory foci. Conceivably, this might also prevent 
ensuing glomerular gene expression changes, preventing remodeling of extracellular 
matrices and progression towards renal failure. Attempts at restoring serum Dnase1 
activity in B/W mice as well as in lupus patients have been generally disappointing 
[164,165]. It is therefore possible that insight into the regulatory mechanisms 
underlying the reduction in renal Dnase1 expression would identify better, more 
targeted strategies to restore renal Dnase1 activity levels.  
The structural and functional changes occurring within the glomerular 
extracellular membranes after immune complex deposition are accompanied by 
changes in the expression of several factors involved in ECM homeostasis. MMP 
activity is increased, possibly by the induction of MMP-2 and -9 by inflammatory 
signals and leukocyte infiltration. Immune complexes containing retained chromatin 
particles can also affect MMP expression through TLR-9 signaling in phagocytosing 
cells [139]. The increased activation of MMPs could have many effects, including 
disruption of normal membrane structure, leading to a dysfunctional filtration barrier. 
An increased turnover of matrix molecules such as collagen IV prevents cross binding 
of fibrils, affecting the compactness and mechanical integrity of the membrane. Such 
changes could also increase the permeability of the membrane allowing increased 
binding of immune complexes. This would generate an amplificatory system of 
inflammatory tissue injury progressing towards end-stage renal failure, as 
schematically illustrated in Figure 4. Also, proteolytic degradation might expose 
antigenic structures that increase the binding affinity of immune complexes and 
autoantibodies. As reviewed in Appendix 2 [72], it has also been proposed that 
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MMPs may unmask cryptic antigens that serve as targets of autoreactivity [166]. 
 
The collagen IV isoform switch that occurs during LN development could represent a 
compensatory response to increased membrane degradation, analogous to the 
deposition of aberrant !1!1!2 matrix within the GBM in Alport syndrome [68], as 
discussed in section 4.4.4. Alternatively, it is also possible that expansion of the 
collagen IV matrix could represent a primary element of the response to mechanical 









that increased MMP activation represents a compensatory response. 
Changes in collagen IV gene expression are likely mediated by pro-fibrotic 
signals. The canonical Wnt/beta-catenin pathway has recently been implicated in the 
pathogenesis of several renal diseases characterized by increased deposition of 
interstitial matrix constituents. Indeed, recent data from our group show that 
stimulation of Wnt-signaling by lithium chloride or over-expression of the Wnt 
antagonist Wnt3a induces changes in collagen IV gene expression in mesangial cells 
that are similar to those seen during LN development (Tveita et al., submitted). 
Likewise, Wnt signaling has been reported to induce expression of matrix 
metalloproteinases, with MMP-2 and MMP-9 constituting potential Wnt-driven target 
genes [83,167]. These findings are supported by recent in vitro data from our lab 
showing that MMP-2 expression is induced by mesangial cells upon stimulation of 
canonical Wnt signaling (Tveita et al., submitted). The observed increase in renal 
canonical Wnt/beta-catenin signaling thus provides a framework to explain at least 
parts of the gene expression changes found to occur within the glomerulus during the 
development and progression of lupus nephritis. In this respect, it is interesting to note 
that the increase in Wnt signaling occurs in the early stages of LN development, 
making it a potentially attractive target for therapeutic interventions targeting 
glomerular remodeling processes.  
 
8.5 Future directions and limitations of the studies 
Like SLE in general, lupus nephritis is a very heterogeneous disease entity. The 
progressive and dynamic nature of lupus nephritis further complicates studies of this 
disease in human subjects. The development of animal models of SLE has therefore 
been an important feat in gaining increased insight into lupus pathophysiology. By 
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allowing studies through the timeline of disease development, the temporal 
association of various events in the pathogenesis can be determined. B/W mouse 
develop nephritis of various histopathological characteristics and severity, resembling 
human LN, and the dominating patterns of immune complex deposition vary 
accordingly. The validity of the present data relies on the assumption that the changes 
occurring in B/W kidneys are analogous to those of human kidneys. Support for such 
assumptions could be sought by immunofluorescence and realtime PCR studies of 
human biopsy material, but sound evidence of temporal associations by repeated 
sampling is made difficult by the invasive nature of renal biopsies. Also, the 
fluctuating and largely unpredictable nature of renal disease in SLE patients is a 
challenge in validating data from studies in mice. 
Evaluating the effects of altered enzyme/signaling pathway activity in mice 
can be achieved by pharmacological means or by genetic modifications. For studies in 
B/W mice, the latter approach is made difficult by the highly inbred nature of the 
species used. Knockout studies in these mice are therefore a lengthy and expensive 
approach. Pharmacological inhibition is easier, but still there is a great variability in 
the age at which disease development occurs, which requires considerable number of 
animals and sound effects of the treatment for the provision of robust data. 
In summary, follow-up data should include verification by studies on human material, 
interventional studies by pharmacological manipulation of relevant factors, and 






9. CONCLUDING REMARKS 
During the last two decades, our understanding of the pathophysiology of lupus 
nephritis has improved considerably. This includes increased knowledge of the 
changes occurring within the glomerular extracellular milieu, and the interaction 
between immune complexes and components of this microenvironment. We now 
know that glomerular immune complexes are largely localized to distinct regions of 
the extracellular membranes containing undigested chromatin particles, with 
chromatin particles functioning as bridging structures between anti-chromatin 
autoantibodies and intrinsic membrane structures like collagen IV and laminins 
[106,107,162]. The finding that renal Dnase1 activity decreases around the time of 
onset of severe nephritis implicates impaired chromatin digestion as a potential 
explanation for the glomerular deposition of chromatin. At the same time, secreted 
metalloproteinase activity increases within the glomerulus, mediating increased 
breakdown of glomerular membranes. The finding that development of lupus 
nephritis is associated with increased activation of the Wnt pathway potentially offers 
a mechanism to explain changes occurring in glomerular extracellular matrix 
turnover. It also identifies an accessible target for pharmacological manipulation of 
renal gene expression, which could potentially affect disease progression, as has been 
seen in experimental models of other renal diseases [81,168]. 
As a whole, these data represent interconnected pieces of a puzzle that offers insight 
into how a systemic autoimmune condition translates into end-organ disease. By 
broadening our understanding into the molecular events underlying such a transition, 
solving this puzzle hopefully will contribute to the development of targeted therapies 





1. Keil H (1937). Conception of lupus erythematosus and its morphologic variants. Arch 
Dermatol Syph 36: 729-757. 
2. Hargraves M (1949). Production in vitro of the L.E. cell phenomenon: use of normal 
bone marrow elements and blood plasma from patients with acute disseminated 
lupus erythematosus. Proc Staff Mayo Clin 24: 234-237. 
3. Rothfield N (1981) Clinical features of systemic lupus erythematosus. In: Kelley W, 
Harris E, Ruddy S, Sledge C, editors. Textbook of Rheumatology. Philadelphia: WB 
Saunders. 
4. Schaller J (1982). Lupus in childhood. Clin Rheum Dis 8: 219-228. 
5. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS (2010). Understanding the 
epidemiology and progression of systemic lupus erythematosus. Semin Arthritis 
Rheum 39: 257-268. 
6. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, et al. (1998). Estimates of 
the prevalence of arthritis and selected musculoskeletal disorders in the United 
States. Arthritis Rheum 41: 778-799. 
7. Uramoto KM, Michet CJ, Jr., Thumboo J, Sunku J, O'Fallon WM, et al. (1999). Trends in 
the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis 
Rheum 42: 46-50. 
8. Lahita RG (1999). The role of sex hormones in systemic lupus erythematosus. Curr 
Opin Rheumatol 11: 352-356. 
9. Lehmann T (1996) Systemic lupus erythematosus in children and adolescents. In: 
Wallace D, Hahn B, editors. Dubois' Systemic Lupus Erythematosus. 5th ed. 
Philadelphia: WB Saunders. 
!48!
10. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, et al. (1992). A revised 
estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35: 
311-318. 
11. Cheung YH, Loh C, Pau E, Kim J, Wither J (2009). Insights into the genetic basis and 
immunopathogenesis of systemic lupus erythematosus from the study of mouse 
models. Semin Immunol 21: 372-382. 
12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982). The 1982 revised 
criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 
1271-1277. 
13. Hochberg MC (1997). Updating the American College of Rheumatology revised 
criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 
1725. 
14. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, et al. (2010). Infections and 
autoimmunity: the multifaceted relationship. J Leukoc Biol 87: 385-395. 
15. Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A (2005). Environment and systemic lupus 
erythematosus: an overview. Autoimmunity 38: 465-472. 
16. Natali PG, Tan EM (1972). Experimental renal disease induced by DNA-anti-DNA 
immune complexes. J Clin Invest 51: 345-355. 
17. Ehrenstein MR, Katz DR, Griffiths MH, Papadaki L, Winkler TH, et al. (1995). Human 
IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. 
Kidney Int 48: 705-711. 
18. Fenton KA, Tømmerås B, Marion TN, Rekvig OP (2010). Pure anti-dsDNA mAbs need 
chromatin structures to promote glomerular mesangial deposits in BALB/c mice. 
Autoimmunity 43: 179-188. 
19. Termaat RM, Assmann KJ, Dijkman HB, van Gompel F, Smeenk RJ, et al. (1992). Anti-
DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 
42: 1363-1371. 
! 49!
20. Matzinger P (1994). Tolerance, danger, and the extended family. Annu Rev Immunol 
12: 991-1045. 
21. Bianchi ME (2007). DAMPs, PAMPs and alarmins: all we need to know about 
danger. J Leukoc Biol 81: 1-5. 
22. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, et al. (2008). Induction 
of inflammatory and immune responses by HMGB1-nucleosome complexes: 
implications for the pathogenesis of SLE. J Exp Med 205: 3007-3018. 
23. Kono H, Rock KL (2008). How dying cells alert the immune system to danger. Nat 
Rev Immunol 8: 279-289. 
24. Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, et al. (2010). Inefficient 
clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, 
HMGB-1 and other players. Apoptosis 15: 1098-1113. 
25. Dieker JWC, van der Vlag J, Berden JHM (2004). Deranged removal of apoptotic cells: 
its role in the genesis of lupus. Nephrol Dial Transplant 19: 282-285. 
26. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, et al. (1998). Impaired 
phagocytosis of apoptotic cell material by monocyte-derived macrophages from 
patients with systemic lupus erythematosus. Arthritis Rheum 41: 1241-1250. 
27. Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, et al. (2010). Inefficient 
clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, 
HMGB-1 and other players. Apoptosis  
28. Gaipl US, Kuhn A, Sheriff A, Munoz LE, Franz S, et al. (2006). Clearance of apoptotic 
cells in human SLE. Curr Dir Autoimmun 9: 173-187. 
29. Walport MJ, Davies KA, Botto M (1998). C1q and systemic lupus erythematosus. 
Immunobiology 199: 265-285. 
30. Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M (1998). High levels of 
circulating early apoptic peripheral blood mononuclear cells in systemic lupus 
erythematosus. Lupus 7: 113-118. 
!50!
31. Courtney PA, Crockard AD, Williamson K, Irvine AE, Kennedy RJ, et al. (1999). 
Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: 
relations with disease activity, antibodies to double stranded DNA, and neutropenia. 
Ann Rheum Dis 58: 309-314. 
32. Gaipl U, Munoz L, Grossmayer G, Lauber K, Franz S, et al. (2007). Clearance 
deficiency and systemic lupus erythematosus (SLE). J Autoimmun 28: 114-121. 
33. Zandman-Goddard G, Shoenfeld Y (2005). Infections and SLE. Autoimmunity 38: 473-
485. 
34. Amit M, Molad Y, Kiss S, Wysenbeek AJ (1997). Seasonal variations in manifestations 
and activity of systemic lupus erythematosus. Br J Rheumatol 36: 449-452. 
35. Petri M, Genovese M, Engle E, Hochberg M (1991). Definition, incidence, and clinical 
description of flare in systemic lupus erythematosus. A prospective cohort study. 
Arthritis Rheum 34: 937-944. 
36. Berzovfsky J, Berkower I, Epstein S (2003) Antigen-Antibody Interactions and 
Monoclonal Antibodies. In: Paul W, editor. Fundamental Immunology. 5th ed. 
Philadelphia: Lipincott Williams & Wilkins. pp. 69-106. 
37. Benacerraf B, Sebestyen M, Cooper NS (1959). The clearance of antigen antibody 
complexes from the blood by the reticuloendothelial system. J Immunol 82: 131-137. 
38. Haakenstad AO, Striker GE, Mannik M (1976). The glomerular deposition of soluble 
immune complexes prepared with reduced and alkylated antibodies and with intact 
antibodies in mice. Lab Invest 35: 293-301. 
39. Arend WP, Mannik M (1971). Studies on antigen-antibody complexes. II. 
Quantification of tissue uptake of soluble complexes in normal and complement-
depleted rabbits. J Immunol 107: 63-75. 
40. Joselow SA, Mannik M (1984). Localization of preformed, circulating immune 
complexes in murine skin. J Invest Dermatol 82: 335-340. 
! 51!
41. Cochrane CG, Hawkins D (1968). Studies on circulating immune complexes. 3. 
Factors governing the ability of circulating complexes to localize in blood vessels. J 
Exp Med 127: 137-154. 
42. Haakenstad AO, Mannik M (1976). The disappearance kinetics of soluble immune 
complexes prepared with reduced and alkylated antibodies and with intact 
antibodies in mice. Lab Invest 35: 283-292. 
43. Lewis RM, Schwartz RS, Gilmore CE (1965). Autoimmune diseases in domestic 
animals. Ann N Y Acad Sci 124: 178-200. 
44. Helyer B, Howie J (1963). Renal disease associated with positive lupus erythematosus 
tests in a cross-bred strain of mice. Nature 197: 197. 
45. Burnet FM, Holmes MC (1965). The natural history of the NZB/NZW F1 hybrid 
mouse: a laboratory model of systemic lupus erythematosus. Australas Ann Med 14: 
185-191. 
46. Baldwin DS, Lowenstein J, Rothfield NF, Gallo G, McCluskey RT (1970). The clinical 
course of the proliferative and membranous forms of lupus nephritis. Ann Intern 
Med 73: 929-942. 
47. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D (1987). Long-term follow-up of 
patients with lupus nephritis. A study based on the classification of the World 
Health Organization. Am J Med 83: 877-885. 
48. Estes D, Christian CL (1971). The natural history of systemic lupus erythematosus by 
prospective analysis. Medicine (Baltimore) 50: 85-95. 
49. Leehey DJ, Katz AI, Azaran AH, Aronson AJ, Spargo BH (1982). Silent diffuse lupus 
nephritis: long-term follow-up. Am J Kidney Dis 2: 188-196. 
50. Wallace D (1992) The clinical presentation of SLE. In: Wallace D, Hahn B, editors. 
Dubois's systemic lupus erythematosus. 4th ed. Philadelphia: Lea & Febiger pp. 317--
321. 
!52!
51. Schur PH, Sandson J (1968). Immunologic factors and clinical activity in systemic 
lupus erythematosus. N Engl J Med 278: 533-538. 
52. Nossent JC, Henzen-Logmans SC, Vroom TM, Huysen V, Berden JH, et al. (1991). 
Relation between serological data at the time of biopsy and renal histology in lupus 
nephritis. Rheumatol Int 11: 77-82. 
53. Forger F, Matthias T, Oppermann M, Becker H, Helmke K (2004). Clinical significance 
of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a 
prognostic marker for lupus nephritis. Lupus 13: 36-44. 
54. Cortes-Hernandez J, Ordi-Ros J, Labrador M, Bujan S, Balada E, et al. (2004). 
Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are 
associated with renal disease in systemic lupus erythematosus. Am J Med 116: 165-
173. 
55. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP (1993). The 
pathogenesis and prognosis of lupus nephritis: information from repeat renal 
biopsy. Semin Arthritis Rheum 23: 135-148. 
56. Lee HS, Mujais SK, Kasinath BS, Spargo BH, Katz AI (1984). Course of renal 
pathology in patients with systemic lupus erythematosus. Am J Med 77: 612-620. 
57. Yoo CW, Kim MK, Lee HS (2000). Predictors of renal outcome in diffuse 
proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol Dial 
Transplant 15: 1604-1608. 
58. Weening J, D'Agati V, Schwartz M, Seshan S, Alpers C, et al. (2004). The classification 
of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 
15: 241-250. 
59. Mannik M, Merrill CE, Stamps LD, Wener MH (2003). Multiple autoantibodies form 
the glomerular immune deposits in patients with systemic lupus erythematosus. J 
Rheumatol 30: 1495-1504. 
60. Lefkowith JB, Gilkeson GS (1996). Nephritogenic autoantibodies in lupus: current 
concepts and continuing controversies. Arthritis Rheum 39: 894-903. 
! 53!
61. van Bavel CC, Fenton KA, Rekvig OP, van der Vlag J, Berden JH (2008). Glomerular 
targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis 
Rheum 58: 1892-1899. 
62. Abrahamson DR (1987). Structure and development of the glomerular capillary wall 
and basement membrane. Am J Physiol 253: F783-794. 
63. Timpl R, Dziadek M (1986). Structure, development, and molecular pathology of 
basement membranes. Int Rev Exp Pathol 29: 1-112. 
64. Makino H, Sugiyama H, Kashihara N (2000). Apoptosis and extracellular matrix-cell 
interactions in kidney disease. Kidney Int Suppl 77: S67-75. 
65. Borza DB, Hudson BG (2003). Molecular characterization of the target antigens of 
anti-glomerular basement membrane antibody disease. Springer Semin Immunopathol 
24: 345-361. 
66. Mjelle JE, Rekvig OP, Fenton KA (2007). Nucleosomes possess high affinity for 
glomerular laminin and collagen IV and bind nephritogenic antibodies in murine 
lupus-like nephritis. Ann Rheum Dis 66: 1661-1668. 
67. Kuhn K (1995). Basement membrane (type IV) collagen. Matrix Biol 14: 439-445. 
68. Hudson BG (2004). The molecular basis of Goodpasture and Alport syndromes: 
beacons for the discovery of the collagen IV family. J Am Soc Nephrol 15: 2514-2527. 
69. Hudson B, Tryggvason K, Sundaramoorthy M, Neilson E (2003). Alport's syndrome, 
Goodpasture's syndrome, and type IV collagen. N Engl J Med 348: 2543-2556. 
70. Spear GS (1974). Pathology of the kidney in Alport's syndrome. Pathol Annu 9: 93-
138. 
71. The Overall lab web page. [http://wwwclipubcca]. 
72. Tveita A, Rekvig OP, Zykova SN (2008). Glomerular matrix metalloproteinases and 
their regulators in the pathogenesis of lupus nephritis. Arthritis Res Ther 10: 229. 
!54!
73. Martin J, Knowlden J, Davies M, Williams J (1994). Identification and independent 
regulation of human mesangial cell metalloproteinases. Kidney Int 46: 877-885. 
74. Xie B, Dong Z, Fidler IJ (1994). Regulatory mechanisms for the expression of type IV 
collagenases/gelatinases in murine macrophages. J Immunol 152: 3637-3644. 
75. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, et al. (1997). 
Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by 
human peripheral blood lymphocytes. J Immunol 158: 2327-2333. 
76. Urushihara M, Kagami S, Kuhara T, Tamaki T, Kuroda Y (2002). Glomerular 
distribution and gelatinolytic activity of matrix metalloproteinases in human 
glomerulonephritis. Nephrol Dial Transplant 17: 1189-1196. 
77. Nakamura T, Ebihara I, Osada S, Takahashi T, Yamamoto M, et al. (1993). Gene 
expression of metalloproteinases and their inhibitor in renal tissue of New Zealand 
black/white F1 mice. Clin Sci (Lond) 85: 295-301. 
78. Nakamura T, Ebihara I, Tomino Y, Koide H (1995). Effect of a specific endothelin A 
receptor antagonist on murine lupus nephritis. Kidney Int 47: 481-489. 
79. Zhang Z, Liu X, Chen G, Zhang X, Guo M (2004). Significance of MMP-2 and TIMP-2 
mRNA expressions on glomerular cells in the development of glomerulosclerosis. 
Chin Med Sci J 19: 84-88. 
80. Ahmed AK, Haylor JL, El Nahas AM, Johnson TS (2007). Localization of matrix 
metalloproteinases and their inhibitors in experimental progressive kidney scarring. 
Kidney Int 71: 755-763. 
81. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, et al. (2009). Wnt/beta-catenin 
signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 20: 
1997-2008. 
82. He W, Dai C, Li Y, Zeng G, Monga SP, et al. (2009). Wnt/beta-catenin signaling 
promotes renal interstitial fibrosis. J Am Soc Nephrol 20: 765-776. 
! 55!
83. Wu B, Crampton SP, Hughes CCW (2007). Wnt signaling induces matrix 
metalloproteinase expression and regulates T cell transmigration. Immunity 26: 227-
239. 
84. Kohn AD, Moon RT (2005). Wnt and calcium signaling: beta-catenin-independent 
pathways. Cell Calcium 38: 439-446. 
85. MacDonald BT, Tamai K, He X (2009). Wnt/beta-catenin signaling: components, 
mechanisms, and diseases. Dev Cell 17: 9-26. 
86. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, et al. (1998). Dickkopf-1 is a 
member of a new family of secreted proteins and functions in head induction. Nature 
391: 357-362. 
87. Luo J, Chen J, Deng ZL, Luo X, Song WX, et al. (2007). Wnt signaling and human 
diseases: what are the therapeutic implications? Lab Invest 87: 97-103. 
88. Surendran K, McCaul SP, Simon TC (2002). A role for Wnt-4 in renal fibrosis. Am J 
Physiol Renal Physiol 282: F431-441. 
89. Surendran K, Schiavi S, Hruska KA (2005). Wnt-dependent beta-catenin signaling is 
activated after unilateral ureteral obstruction, and recombinant secreted frizzled-
related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 16: 2373-
2384. 
90. Lin C-L, Wang J-Y, Huang Y-T, Kuo Y-H, Surendran K, et al. (2006). Wnt/beta-catenin 
signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc 
Nephrol 17: 2812-2820. 
91. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, et al. (2001). Wnt-1 signaling 
inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J 
Cell Biol 152: 87-96. 
92. Shou J, Ali-Osman F, Multani AS, Pathak S, Fedi P, et al. (2002). Human Dkk-1, a gene 
encoding a Wnt antagonist, responds to DNA damage and its overexpression 
sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. 
Oncogene 21: 878-889. 
!56!
93. Mikheev AM, Mikheeva SA, Rostomily R, Zarbl H (2007). Dickkopf-1 activates cell 
death in MDA-MB435 melanoma cells. Biochem Biophys Res Commun 352: 675-680. 
94. Mikheev AM, Mikheeva SA, Liu B, Cohen P, Zarbl H (2004). A functional genomics 
approach for the identification of putative tumor suppressor genes: Dickkopf-1 as 
suppressor of HeLa cell transformation. Carcinogenesis 25: 47-59. 
95. Mikheev AM, Mikheeva SA, Maxwell JP, Rivo JV, Rostomily R, et al. (2008). Dickkopf-
1 mediated tumor suppression in human breast carcinoma cells. Breast Cancer Res 
Treat 112: 263-273. 
96. Cheng JH, She H, Han YP, Wang J, Xiong S, et al. (2008). Wnt antagonism inhibits 
hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver 
Physiol 294: G39-49. 
97. Lee AY, He B, You L, Xu Z, Mazieres J, et al. (2004). Dickkopf-1 antagonizes Wnt 
signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res 
Commun 323: 1246-1250. 
98. Peng S, Miao C, Li J, Fan X, Cao Y, et al. (2006). Dickkopf-1 induced apoptosis in 
human placental choriocarcinoma is independent of canonical Wnt signaling. 
Biochem Biophys Res Commun 350: 641-647. 
99. Long L, Liu Y, Wang S, Zhao Y, Guo J, et al. (2010). Dickkopf-1 as Potential 
Biomarker to Evaluate Bone Erosion in Systemic Lupus Erythematosus. J Clin 
Immunol 30: 669-675. 
100. Rahman A, Isenberg DA (2008). Systemic lupus erythematosus. N Engl J Med 358: 
929-939. 
101. Stockl F, Muller S, Batsford S, Schmiedeke T, Waldherr R, et al. (1994). A role for 
histones and ubiquitin in lupus nephritis? Clin Nephrol 41: 10-17. 
102. Schmiedeke T, Stoeckl F, Muller S, Sugisaki Y, Batsford S, et al. (1992). Glomerular 
immune deposits in murine lupus models may contain histones. Clin Exp Immunol 
90: 453-458. 
! 57!
103. Monestier M, Novick KE, Karam ET, Chabanne L, Monier JC, et al. (1995). 
Autoantibodies to histone, DNA and nucleosome antigens in canine systemic lupus 
erythematosus. Clin Exp Immunol 99: 37-41. 
104. Meziere C, Stockl F, Batsford S, Vogt A, Muller S (1994). Antibodies to DNA, 
chromatin core particles and histones in mice with graft-versus-host disease and 
their involvement in glomerular injury. Clin Exp Immunol 98: 287-294. 
105. Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, et al. (2007). Glomerular 
apoptotic nucleosomes are central target structures for nephritogenic antibodies in 
human SLE nephritis. Kidney Int 71: 664-672. 
106. Kalaaji M, Mortensen ES, Jørgensen L, Olsen R, Rekvig OP (2006). Nephritogenic 
lupus antibodies recognize glomerular basement membrane-associated chromatin 
fragments released from apoptotic intraglomerular cells. Am J Pathol 168: 1779-
1792. 
107. Mortensen ES, Fenton KA, Rekvig OP (2008). Lupus nephritis: the central role of 
nucleosomes revealed. Am J Pathol 172: 275-283. 
108. Fenton KA, Rekvig OP (2007). A central role of nucleosomes in lupus nephritis. Ann 
N Y Acad Sci 1108: 104-113. 
109. Samejima K, Earnshaw WC (2005). Trashing the genome: the role of nucleases 
during apoptosis. Nat Rev Mol Cell Biol 6: 677-688. 
110. Wyllie AH (1980). Glucocorticoid-induced thymocyte apoptosis is associated with 
endogenous endonuclease activation. Nature 284: 555-556. 
111. Earnshaw WC (1995). Nuclear changes in apoptosis. Curr Opin Cell Biol 7: 337-343. 
112. Scaffidi P, Misteli T, Bianchi ME (2002). Release of chromatin protein HMGB1 by 
necrotic cells triggers inflammation. Nature 418: 191-195. 
113. van Nieuwenhuijze AE, van Lopik T, Smeenk RJ, Aarden LA (2003). Time between 
onset of apoptosis and release of nucleosomes from apoptotic cells: putative 
implications for systemic lupus erythematosus. Ann Rheum Dis 62: 10-14. 
!58!
114. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA (2000). Plasma DNA as a 
prognostic marker in trauma patients. Clin Chem 46: 319-323. 
115. Chang CP, Chia RH, Wu TL, Tsao KC, Sun CF, et al. (2003). Elevated cell-free serum 
DNA detected in patients with myocardial infarction. Clin Chim Acta 327: 95-101. 
116. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977). Free DNA in the serum of cancer 
patients and the effect of therapy. Cancer Res 37: 646-650. 
117. Tan EM, Schur PH, Carr RI, Kunkel HG (1966). Deoxybonucleic acid (DNA) and 
antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin 
Invest 45: 1732-1740. 
118. McCoubrey-Hoyer A, Okarma TB, Holman HR (1984). Partial purification and 
characterization of plasma DNA and its relation to disease activity in systemic lupus 
erythematosus. Am J Med 77: 23-34. 
119. Amoura Z, Piette JC, Chabre H, Cacoub P, Papo T, et al. (1997). Circulating plasma 
levels of nucleosomes in patients with systemic lupus erythematosus: correlation 
with serum antinucleosome antibody titers and absence of clear association with 
disease activity. Arthritis Rheum 40: 2217-2225. 
120. Kanai Y, Kyuwa S, Miura K, Kurosawa Y (1995). Induction and natural occurrence 
of serum nucleosomal DNA in autoimmune MRL/lpr/lpr mice: its relation to 
apoptosis in the thymus. Immunol Lett 46: 207-214. 
121. Berden JH, Grootscholten C, Jurgen WC, van der Vlag J (2002). Lupus nephritis: a 
nucleosome waste disposal defect? J Nephrol 15 Suppl 6: S1-10. 
122. Gaipl U, Voll R, Sheriff A, Franz S, Kalden J, et al. (2005). Impaired clearance of 
dying cells in systemic lupus erythematosus. Autoimmun Rev 4: 189-194. 
123. Frost PG, Lachmann PJ (1968). The relationship of desoxyribonuclease inhibitor 
levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol 
3: 447-455. 
! 59!
124. Nadano D, Yasuda T, Kishi K (1993). Measurement of deoxyribonuclease I activity in 
human tissues and body fluids by a single radial enzyme-diffusion method. Clin 
Chem 39: 448-452. 
125. Chitrabamrung S, Bannett JS, Rubin RL, Tan EM (1981). A radial diffusion assay for 
plasma and serum deoxyribonuclease I. Rheumatol Int 1: 49-53. 
126. Napirei M, Wulf S, Eulitz D, Mannherz HG, Kloeckl T (2005). Comparative 
characterization of rat deoxyribonuclease 1 (Dnase1) and murine deoxyribonuclease 
1-like 3 (Dnase1l3). Biochem J 389: 355-364. 
127. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, et al. (2000). Features of 
systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25: 177-181. 
128. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, et al. (2001). 
Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 28: 
313-314. 
129. Chitrabamrung S, Rubin RL, Tan EM (1981). Serum deoxyribonuclease I and clinical 
activity in systemic lupus erythematosus. Rheumatol Int 1: 55-60. 
130. Macanovic M, Lachmann PJ (1997). Measurement of deoxyribonuclease I (DNase) in 
the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice 
by a new radial enzyme diffusion assay. Clin Exp Immunol 108: 220-226. 
131. Yeh T-M, Chang H-C, Liang C-C, Wu J-J, Liu M-F (2003). Deoxyribonuclease-
inhibitory antibodies in systemic lupus erythematosus. J Biomed Sci 10: 544-551. 
132. Zykova SN, Seredkina N, Benjaminsen J, Rekvig OP (2008). Reduced fragmentation 
of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x 
NZW)F(1) mice. Arthritis Rheum 58: 813-825. 
133. Fenton K, Fismen S, Hedberg A, Seredkina N, Fenton C, et al. (2009). Anti-dsDNA 
antibodies promote initiation, and acquired loss of renal Dnase1 promotes 
progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. PLoS ONE 4: 
e8474. 
!60!
134. Mortensen ES, Rekvig OP (2009). Nephritogenic potential of anti-DNA antibodies 
against necrotic nucleosomes. J Am Soc Nephrol 20: 696-704. 
135. Fismen S, Mortensen ES, Rekvig OP (2010). Nuclease deficiencies promote end-stage 
lupus nephritis but not nephritogenic autoimmunity in (NZB x NZW) F1 mice. 
Immunol Cell Biol. 
136. Galis Z, Sukhova G, Libby P (1995). Microscopic localization of active proteases by 
in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. 
Faseb J 9: 974-980. 
137. Zeisberg M, Ericksen MB, Hamano Y, Neilson EG, Ziyadeh F, et al. (2002). 
Differential expression of type IV collagen isoforms in rat glomerular endothelial 
and mesangial cells. Biochem Biophys Res Commun 295: 401-407. 
138. Lim EJ, Lee SH, Lee JG, Kim JR, Yun SS, et al. (2007). Toll-like receptor 9 dependent 
activation of MAPK and NF-kB is required for the CpG ODN-induced matrix 
metalloproteinase-9 expression. Exp Mol Med 39: 239-245. 
139. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, et al. (2006). Toll-like 
receptor 9 agonists promote cellular invasion by increasing matrix 
metalloproteinase activity. Mol Cancer Res 4: 437-447. 
140. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, et al. (2002). 
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like 
receptors. Nature 416: 603-607. 
141. von Luttichau I, Djafarzadeh R, Henger A, Cohen CD, Mojaat A, et al. (2002). 
Identification of a signal transduction pathway that regulates MMP-9 mRNA 
expression in glomerular injury. Biol Chem 383: 1271-1275. 
142. Serluca FC, Drummond IA, Fishman MC (2002). Endothelial signaling in kidney 
morphogenesis: a role for hemodynamic forces. Curr Biol 12: 492-497. 
143. Catania JM, Chen G, Parrish AR (2007). Role of matrix metalloproteinases in renal 
pathophysiologies. Am J Physiol Renal Physiol 292: F905-911. 
! 61!
144. Hu J, Van den Steen PE, Sang QX, Opdenakker G (2007). Matrix metalloproteinase 
inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 
6: 480-498. 
145. Liu Y (2006). Renal fibrosis: new insights into the pathogenesis and therapeutics. 
Kidney Int 69: 213-217. 
146. Marti H (2000). New strategy to treat glomerular inflammation by inhibition of 
mesangial cell matrix metalloproteinases. Schweiz Med Wochenschr 130: 784-788. 
147. Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, et al. (2007). Urinary lipocalin-
2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 
56: 1894-1903. 
148. Rubinstein T, Pitashny M, Putterman C (2008). The novel role of neutrophil 
gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus 
nephritis. Autoimmun Rev 7: 229-234. 
149. Seredkina N, Zykova S, Rekvig O (2009). Progression of murine lupus nephritis is 
linked to acquired renal Dnase1 deficiency and not to up-regulated apoptosis. Am J 
Pathol 175: 97-106. 
150. Zykova SN, Tveita AA, Rekvig OP (2010). Renal Dnase1 Enzyme Activity and 
Protein Expression Is Selectively Shut Down in Murine and Human 
Membranoproliferative Lupus Nephritis. PLoS ONE 5: e12096. 
151. Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, et al. 
(2009). DNase 1 activity in patients with systemic lupus erythematosus: relationship 
with epidemiological, clinical, immunological and therapeutical features. Lupus 18: 
418-423. 
152. Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, et al. 
(2009). DNase1 activity in systemic lupus erythematosus patients with and without 
nephropathy. Rheumatology international. 
!62!
153. Yasuhara R, Yuasa T, Williams JA, Byers SW, Shah S, et al. (2010). Wnt/beta-catenin 
and retinoic acid receptor signaling pathways interact to regulate chondrocyte 
function and matrix turnover. J Biol Chem 285: 317-327. 
154. Yuasa T, Otani T, Koike T, Iwamoto M, Enomoto-Iwamoto M (2008). Wnt/beta-
catenin signaling stimulates matrix catabolic genes and activity in articular 
chondrocytes: its possible role in joint degeneration. Lab Invest 88: 264-274. 
155. Ryu JH, Chun JS (2006). Opposing roles of WNT-5A and WNT-11 in interleukin-
1beta regulation of type II collagen expression in articular chondrocytes. J Biol 
Chem 281: 22039-22047. 
156. Gonzalez-Sancho JM, Aguilera O, Garcia JM, Pendas-Franco N, Pena C, et al. (2005). 
The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF 
and is downregulated in human colon cancer. Oncogene 24: 1098-1103. 
157. Wang J, Shou J, Chen X (2000). Dickkopf-1, an inhibitor of the Wnt signaling 
pathway, is induced by p53. Oncogene 19: 1843-1848. 
158. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, et al. (2007). Antibody-based 
inhibition of DKK1 suppresses tumor-induced bone resorption and multiple 
myeloma growth in vivo. Blood 109: 2106-2111. 
159. Couzi L, Merville P, Deminiere C, Moreau JF, Combe C, et al. (2007). Predominance 
of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the 
prognosis of class III and class IV lupus nephritis. Arthritis Rheum 56: 2362-2370. 
160. Foster MH (2007). T cells and B cells in lupus nephritis. Semin Nephrol 27: 47-58. 
161. Kramers C, Hylkema MN, van Bruggen MC, van de Lagemaat R, Dijkman HB, et al. 
(1994). Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-
DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 
94: 568-577. 
162. Kalaaji M, Sturfelt G, Mjelle JE, Nossent H, Rekvig OP (2006). Critical comparative 
analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and 
murine lupus nephritis. Arthritis Rheum 54: 914-926. 
! 63!
163. van Bruggen MC, Kramers C, Walgreen B, Elema JD, Kallenberg CG, et al. (1997). 
Nucleosomes and histones are present in glomerular deposits in human lupus 
nephritis. Nephrol Dial Transplant 12: 57-66. 
164. Verthelyi D, Dybdal N, Elias KA, Klinman DM (1998). DNAse treatment does not 
improve the survival of lupus prone (NZB x NZW)F1 mice. Lupus 7: 223-230. 
165. Davis JC, Manzi S, Yarboro C, Rairie J, Mcinnes I, et al. (1999). Recombinant human 
Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8: 68-76. 
166. Opdenakker G, Dillen C, Fiten P, Martens E, Van Aelst I, et al. (2006). Remnant 
epitopes, autoimmunity and glycosylation. Biochim Biophys Acta 1760: 610-615. 
167. Sonderegger S, Haslinger P, Sabri A, Leisser C, Otten JV, et al. (2010). Wingless 
(Wnt)-3A induces trophoblast migration and matrix metalloproteinase-2 secretion 
through canonical Wnt signaling and protein kinase B/AKT activation. 
Endocrinology 151: 211-220. 
168. Hwang I, Seo E-y, Ha H (2009). Wnt/beta-catenin signaling: a novel target for 








































Appendix 1  
1982 revised systemic lupus erythematosus classification criteria  
Criterion Definition 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and 
follicular plugging: atrophic scarring may occur in older lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a 
physician 
5. Arthritis Nonerosive arthritis involving ! 2 peripheral joints, characterized by 
tenderness, swelling, or effusion 
6. Serositis (A) Pleuritis: convincing history of pleuritic pain or rub heard by a 
physician or evidence of pleural effusion 
or 
(B) Pericarditis: documented by ECG or rub or evidence of pericardial 
effusion 
7. Renal disorder (A) Persistent proteinuria >0.5 g/d or >3+ if quantitation not performed 
or 
B) Cellular casts: may be red blood cell, hemoglobin, granular, tubular, 
or mixed 
8. Neurologic disorder (A) Seizures: in the absence of offending drugs or known metabolic 
derangements (eg, uremia, ketoacidosis, or electrolyte imbalance) 
or 
(B) Psychosis: in the absence of offending drugs or known metabolic 
derangements (eg, uremia, ketoacidosis, or electrolyte imbalance) 
9. Hematologic disorder (A) Hemolytic anemia: with reticulocytosis 
Criterion Definition 
or 
(B) Leukopenia: <4000/mm3 total on !2 occasions 
or 
(C) Lymphopenia: <1500/mm3 on !2 occasions 
or 
(D) Thrombocytopenia: <100,000/mm3 in the absence of offending drugs 
10. Immunologic  
      disorder 
(A) Positive antiphospholipid antibody 
or 
(B) Anti-DNA: antibody to native DNA in abnormal titer 
or 
(C) Anti-Sm: presence of antibody to Sm nuclear antigen 
or 
(D) False positive serologic test for syphilis known to be positive for at 
least 6 months and confirmed by T pallidum immobilization or 
fluorescent treponemal antibody absorption test 
11. Antinuclear antibody An abnormal titer of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs known 
to be associated with “drug-induced lupus” syndrome 
The proposed classification is based on 11 criteria. For the purpose of identifying patients in 
clinical studies, a person shall be said to have systemic lupus erythematosus if any 4 or more of 
the 11 criteria are present, serially or simultaneously, during any interval of observation. 
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